Stockscreener 앱 받기
39.73
3.73%
-1.57
전일 마감가:
$41.30
열려 있는:
$40.61
하루 거래량:
428.85K
Relative Volume:
0.36
시가총액:
$4.93B
수익:
$10.60M
순이익/손실:
$-252.45M
주가수익비율:
-12.82
EPS:
-3.1
순현금흐름:
$-158.91M
1주 성능:
-9.22%
1개월 성능:
-5.04%
6개월 성능:
+47.75%
1년 성능:
+390.86%
1일 변동 폭
$39.73
$41.46
1주일 범위
$39.76
$44.52
52주 변동 폭
$6.79
$56.00
어비디티 바이오사이언스 Stock (RNA) Company Profile
명칭
Avidity Biosciences Inc
전화
858-401-7900
주소
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
RNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
39.73 | 4.93B | 10.60M | -252.45M | -158.91M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.17 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.07 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
620.93 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.47 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.73 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
어비디티 바이오사이언스 Stock (RNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-09-24 | 개시 | Goldman | Buy |
| 2024-08-28 | 개시 | Barclays | Overweight |
| 2024-05-03 | 개시 | BofA Securities | Buy |
| 2024-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-05-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Strong Buy |
| 2021-09-07 | 개시 | Evercore ISI | Outperform |
| 2021-06-17 | 개시 | Needham | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | Cowen | Outperform |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | SVB Leerink | Outperform |
| 2020-07-07 | 개시 | Wells Fargo | Overweight |
모두보기
어비디티 바이오사이언스 주식(RNA)의 최신 뉴스
Charles Schwab Investment Management Inc. Purchases 197,065 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Alethea Capital Management LLC Reduces Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights - GuruFocus.com
Avidity Biosciences Announces New Precision Cardiology Developme - GuruFocus.com
Myotonic dystrophy pipeline shows momentum - The Pharma Letter
Fmr LLC Has $773.86 Million Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Dyne, Avidity initiated at outperform by RBC on DM1 drugs (NASDAQ:DYN) - Seeking Alpha
Avidity Biosciences to Present at Evercore ISI HealthCONx Conference | RNA Stock News - StockTitan
Avidity Biosciences (NASDAQ:RNA) Earns Outperform Rating from Analysts at Royal Bank of Canada - MarketBeat
RBC Capital initiates Avidity Biosciences shares with Outperform rating By Investing.com - Investing.com Canada
Intech Investment Management LLC Makes New $1.70 Million Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Holdings Boosted by Victory Capital Management Inc. - MarketBeat
RNA's SWOT analysis: promising pipeline drives biotech stock potential - Investing.com
Connor Clark & Lunn Investment Management Ltd. Boosts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Financial Times
Avidity Biosciences Awards $43.65 Stock Options, RSUs to New Employees | RNA Stock News - StockTitan
Avidity Biosciences director Arthur Levin sells $139,972 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences director Arthur Levin sells $139,972 in stock - Investing.com India
Avidity Biosciences' chief HR officer Teresa McCarthy sells $1.03m in stock - Investing.com Canada
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for - MSN
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News - MSN
Mutual of America Capital Management LLC Sells 19,252 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Research Analysts Set Expectations for RNA FY2024 Earnings - MarketBeat
Los Angeles Capital Management LLC Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
State of New Jersey Common Pension Fund D Buys Shares of 44,898 Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
12,319 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Purchased by Assetmark Inc. - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Shares Down 7.8%Time to Sell? - MarketBeat
RA Capital Management's Strategic Acquisition in Avidity Bioscie - GuruFocus.com
Avoro Capital Advisors LLC Increases Stake in Avidity Biosciences Inc - GuruFocus.com
Avidity Biosciences unveils new cardiology development candidates - BioWorld Online
RNA Stock Hits Record High on Entering the Cardiac Disease Space - Yahoo Finance
US Bancorp DE Cuts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences stock soars to all-time high of $50.86 By Investing.com - Investing.com Canada
Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1 - Quantisnow
Avidity Biosciences stock soars to all-time high of $50.86 - Investing.com
Avidity Biosciences jumps 16%; reaches all-time high (RNA:NASDAQ) - Seeking Alpha
Avidity Biosciences (NASDAQ:RNA) Reaches New 1-Year HighShould You Buy? - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Assessing Avidity Biosciences: Insights From 10 Financial Analysts - Benzinga
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PR Newswire
Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights - GuruFocus.com
Avidity Biosciences (RNA) Stock Surges On Positive AOC 1020 Trial Results - Barchart
Avidity Biosciences' SWOT analysis: RNA stock poised for growth in precision cardiology - Investing.com
Avidity Biosciences Unveils Advances in Cardiology Research - TipRanks
Avidity Biosciences, Inc. Announces AOC 1072 and AOC 1086 as Initial Precision Cardiology Development Candidates and Shared First Look At Its Next-Generation Technology Innovations - Marketscreener.com
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations - Quantisnow
Selling US$1.0m Of Avidity Biosciences Stock Rewarded Insiders - Simply Wall St
Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Canada Finance
431,210 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Fiera Capital Corp - MarketBeat
어비디티 바이오사이언스 (RNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
어비디티 바이오사이언스 주식 (RNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| McCarthy Teresa | Chief Human Resources Officer |
Nov 18 '24 |
Sale |
41.14 |
25,000 |
1,028,520 |
94,018 |
| LEVIN ARTHUR A | Director |
Nov 19 '24 |
Option Exercise |
1.24 |
3,323 |
4,121 |
18,153 |
| LEVIN ARTHUR A | Director |
Nov 19 '24 |
Sale |
42.12 |
3,323 |
139,973 |
14,830 |
| MacLean Michael F | Chief Financial Officer |
Nov 06 '24 |
Option Exercise |
8.43 |
79,057 |
666,064 |
159,275 |
| MacLean Michael F | Chief Financial Officer |
Nov 06 '24 |
Sale |
45.56 |
106,319 |
4,843,979 |
94,093 |
1.05%
0.10%
자본화:
|
볼륨(24시간):